Protocols
1 protocol(s) meet the specified criteria
Drug: Seribantumab
Protocol No.	Title	Status
MM-121-02-02-10	SHERBOC: A Double-blind, Placebo-controlled, Phase 2 trial of Seribantumab Plus Fulvestrant in Postmenopausal Women with Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Systemic Therapy	Open